Skip to main content
Quest Diagnostics

A Definitive High-Throughput Assay for Cyclobenzaprine, Norcyclobenzaprine, Dextromethorphan, and Dextrorphan in Urine

ADLM 2026

Association for Diagnostics and Laboratory Medicine

Anaheim, CA, June 26-30, 2026,

Poster presentation: A Definitive High-Throughput Assay for Cyclobenzaprine, Norcyclobenzaprine, Dextromethorphan, and Dextrorphan in Urine

Authors: Anita DerMartirosian and Karin Thomassian

Medical Specialty: Prescription Drug Monitoring, Toxicology

Related content

Audio Podcast
Novel Psychoactive Substances (NPS): A Dangerous, Widespread Public Health Issue
Test FAQ
Drug Monitoring Antidepressants With Confirmation Urine and Serum
On-Demand Webinar
The Growing Crisis of Novel Psychoactive Substances
Test FAQ
Pain Management Antipsychotics With Confirmation Serum and Urine

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.